28193256|t|Unbiased estimates of cerebrospinal fluid β-amyloid 1-42 cutoffs in a large memory clinic population
28193256|a|We sought to define a cutoff for β-amyloid 1-42 in cerebrospinal fluid (CSF), a key marker for Alzheimer's disease (AD), with data-driven Gaussian mixture modeling in a memory clinic population. We performed a combined cross-sectional and prospective cohort study. We selected 2462 subjects with subjective cognitive decline, mild cognitive impairment, AD -type dementia, and dementia other than AD from the Amsterdam Dementia Cohort. We defined CSF β-amyloid 1-42 cutoffs by data-driven Gaussian mixture modeling in the total population and in subgroups based on clinical diagnosis, age, and apolipoprotein E (APOE) genotype. We investigated whether abnormal β-amyloid 1-42 as defined by the data-driven cutoff could better predict progression to AD -type dementia than abnormal β-amyloid 1-42 defined by a clinical diagnosis -based cutoff using Cox proportional hazards regression. In the total group of patients, we found a cutoff for abnormal CSF β-amyloid 1-42 of 680 pg/ml (95% CI 660-705 pg/ml). Similar cutoffs were found within diagnostic and APOE genotype subgroups. The cutoff was higher in elderly subjects than in younger subjects. The data-driven cutoff was higher than our clinical diagnosis -based cutoff and had a better predictive accuracy for progression to AD -type dementia in nondemented subjects (HR 7.6 versus 5.2, p < 0.01). Mixture modeling is a robust method to determine cutoffs for CSF β-amyloid 1-42. It might better capture biological changes that are related to AD than cutoffs based on clinical diagnosis.
28193256	0	18	Unbiased estimates	T062	C1711255
28193256	22	41	cerebrospinal fluid	T031	C0007806
28193256	42	56	β-amyloid 1-42	T116,T123	C0169424
28193256	57	64	cutoffs	T169	C1442160
28193256	76	89	memory clinic	T073,T093	C0442592
28193256	90	100	population	T098	C1257890
28193256	123	129	cutoff	T169	C1442160
28193256	134	148	β-amyloid 1-42	T116,T123	C0169424
28193256	152	171	cerebrospinal fluid	T031	C0007806
28193256	173	176	CSF	T031	C0007806
28193256	185	191	marker	T201	C0005516
28193256	196	215	Alzheimer's disease	T047	C0002395
28193256	217	219	AD	T047	C0002395
28193256	227	238	data-driven	T080	C3899452
28193256	239	264	Gaussian mixture modeling	T081,T170	C0026348
28193256	270	283	memory clinic	T073,T093	C0442592
28193256	284	294	population	T098	C1257890
28193256	320	335	cross-sectional	T062	C0010362
28193256	340	364	prospective cohort study	T062	C1709709
28193256	383	391	subjects	T098	C2349001
28193256	397	425	subjective cognitive decline	T046	C0234985
28193256	427	452	mild cognitive impairment	T048	C1270972
28193256	454	456	AD	T047	C0002395
28193256	463	471	dementia	T048	C0497327
28193256	477	485	dementia	T048	C0497327
28193256	497	499	AD	T047	C0002395
28193256	509	518	Amsterdam	UnknownType	C0681784
28193256	519	527	Dementia	T048	C0497327
28193256	528	534	Cohort	T098	C0599755
28193256	547	550	CSF	T031	C0007806
28193256	551	565	β-amyloid 1-42	T116,T123	C0169424
28193256	566	573	cutoffs	T169	C1442160
28193256	577	588	data-driven	T080	C3899452
28193256	589	614	Gaussian mixture modeling	T081,T170	C0026348
28193256	622	638	total population	T081	C3258257
28193256	646	655	subgroups	T185	C1515021
28193256	665	683	clinical diagnosis	T060	C0332140
28193256	685	688	age	T032	C0001779
28193256	694	726	apolipoprotein E (APOE) genotype	T059	C1446118
28193256	731	743	investigated	T169	C1292732
28193256	752	760	abnormal	T033	C0205161
28193256	761	775	β-amyloid 1-42	T116,T123	C0169424
28193256	794	805	data-driven	T080	C3899452
28193256	806	812	cutoff	T169	C1442160
28193256	826	833	predict	T078	C0681842
28193256	834	845	progression	T169	C0449258
28193256	849	851	AD	T047	C0002395
28193256	858	866	dementia	T048	C0497327
28193256	872	880	abnormal	T033	C0205161
28193256	881	895	β-amyloid 1-42	T116,T123	C0169424
28193256	909	927	clinical diagnosis	T060	C0332140
28193256	935	941	cutoff	T169	C1442160
28193256	948	983	Cox proportional hazards regression	T081,T170	C0010235
28193256	998	1003	group	T078	C0441833
28193256	1007	1015	patients	T101	C0030705
28193256	1028	1034	cutoff	T169	C1442160
28193256	1039	1047	abnormal	T033	C0205161
28193256	1048	1051	CSF	T031	C0007806
28193256	1052	1066	β-amyloid 1-42	T116,T123	C0169424
28193256	1085	1087	CI	T081	C0009667
28193256	1112	1119	cutoffs	T169	C1442160
28193256	1138	1148	diagnostic	T033	C0011900
28193256	1153	1166	APOE genotype	T059	C1446118
28193256	1167	1176	subgroups	T185	C1515021
28193256	1182	1188	cutoff	T169	C1442160
28193256	1193	1199	higher	T080	C0205250
28193256	1203	1210	elderly	T098	C0001792
28193256	1211	1219	subjects	T098	C2349001
28193256	1236	1244	subjects	T098	C2349001
28193256	1250	1261	data-driven	T080	C3899452
28193256	1262	1268	cutoff	T169	C1442160
28193256	1273	1279	higher	T080	C0205250
28193256	1289	1307	clinical diagnosis	T060	C0332140
28193256	1315	1321	cutoff	T169	C1442160
28193256	1339	1349	predictive	T080	C0681890
28193256	1350	1358	accuracy	T080	C0443131
28193256	1363	1374	progression	T169	C0449258
28193256	1378	1380	AD	T047	C0002395
28193256	1387	1395	dementia	T048	C0497327
28193256	1411	1419	subjects	T098	C2349001
28193256	1421	1423	HR	T081	C2985465
28193256	1440	1441	p	T081	C1709380
28193256	1451	1467	Mixture modeling	T081,T170	C0026348
28193256	1473	1479	robust	T080	C2986815
28193256	1480	1486	method	T170	C0025663
28193256	1500	1507	cutoffs	T169	C1442160
28193256	1512	1515	CSF	T031	C0007806
28193256	1516	1530	β-amyloid 1-42	T116,T123	C0169424
28193256	1556	1566	biological	T080	C0205460
28193256	1567	1574	changes	T169	C0392747
28193256	1595	1597	AD	T047	C0002395
28193256	1603	1610	cutoffs	T169	C1442160
28193256	1620	1638	clinical diagnosis	T060	C0332140